425: BioCryst Acquires Astria, Boosts HAE Portfolio

BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in equity value, adding a late-stage HAE treatment and strengthening its rare disease pipeline.

Summary

• BioCryst Pharmaceuticals, Inc. (BioCryst) is acquiring Astria Therapeutics, Inc. (Astria) through a merger, with Astria becoming a wholly-owned subsidiary of BioCryst.
• The merger consideration for each Astria share consists of $8.55 in cash and 0.59 shares of BioCryst common stock.
• This represents an implied value of $13.00 per Astria share, totaling approximately $920 million in aggregate equity value and $700 million in enterprise value.
• The implied value per share is a premium of approximately 53% over Astria's closing share price on October 13, 2025, and 71% over its 20-day VWAP as of October 13, 2025.
• Astria stockholders are expected to own approximately 15% of the proforma equity in the combined company.
• The key asset acquired is navenibart (formerly STAR-0215), an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein for hereditary angioedema (HAE) prophylaxis, currently in Phase 3 clinical development.
• BioCryst will also obtain Astria's early-stage program for atopic dermatitis, STAR-0310, and plans to seek strategic alternatives for this asset.
• BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction, with the deal anticipated to be accretive to operating profit (non-GAAP) in the first full year of navenibart's anticipated launch.
• BioCryst paid off its remaining debt from Pharmakon on October 8, 2025, and secured a new $550,000,000 senior secured credit facility from affiliates of Blackstone, Inc. to fund the cash portion of the acquisition.
• The transaction was unanimously approved by both BioCryst and Astria Boards of Directors and is expected to close in the first quarter of 2026, subject to customary closing conditions and Astria stockholder approval.
• Certain Astria stockholders, including directors, executive officers, and affiliates of Perceptive Advisors L.L.C., have entered into voting and support agreements in favor of the transaction.

Sentiment

Score: 8

Explanation: The acquisition is a highly strategic move that significantly enhances BioCryst's position in the Hereditary Angioedema (HAE) market with a promising late-stage asset. The financial terms appear favorable for Astria shareholders, and BioCryst projects continued profitability and strong growth, supported by new financing and existing business strength. While new debt is incurred, the overall strategic and financial outlook is positive.

Positives

• Acquisition of navenibart, a late-stage (Phase 3) and potentially best-in-class injectable HAE treatment, significantly expanding BioCryst's core HAE portfolio.
• Navenibart offers a highly differentiated 3and 6-month administration schedule and pain-free dosing, addressing key unmet needs in the HAE patient community.
• The transaction is expected to transform BioCryst's long-term revenue growth trajectory, extending double-digit revenue growth through the next decade.
• BioCryst anticipates continued profitability (non-GAAP) and positive cash flow post-transaction.
• The acquisition is expected to be significantly accretive to operating profit (non-GAAP) in the first full year of navenibart's anticipated launch, leveraging BioCryst's existing commercial infrastructure.
• Strong cash flow generation is expected, with a projected cash balance of over $1 billion by 2029, enabling optionality for other growth opportunities.
• BioCryst's ORLADEYO product showed strong demand in Q3 2025, in line with past performance and without impact from new competition, indicating a robust existing business.
• The implied $13.00 value per Astria share represents a substantial premium (53% over October 13, 2025 closing price, 71% over 20-day VWAP) for Astria stockholders.
• BioCryst paid off its previous debt from Pharmakon on October 8, 2025, prior to securing new financing for this acquisition, improving its financial flexibility.

Negatives

• BioCryst expects to incur significant indebtedness in connection with the transaction, requiring sufficient cash flows for service and repayment.
• There is a potential dilutive effect on BioCryst common stock due to shares issued in the transaction.
• The early-stage program for atopic dermatitis, STAR-0310, is considered non-core, and BioCryst plans to seek strategic alternatives, indicating it is not a primary value driver for the acquisition.
• The transaction may be more expensive to complete than anticipated, and anticipated benefits and synergies may not be fully realized.
• The merger could divert management's attention from ongoing business operations and opportunities.

Risks

• The occurrence of any event, change, or circumstances that could give rise to the right of one or both parties to terminate the Merger Agreement.
• The outcome of any legal proceedings that may be instituted against BioCryst or Astria related to the merger.
• Failure to obtain necessary regulatory approvals (e.g., HSR Act) or Astria stockholder approval, or the imposition of adverse conditions by regulators.
• The possibility that anticipated benefits of the merger, including synergies, are not realized when expected or at all, potentially due to integration problems or competitive factors.
• The significant indebtedness BioCryst expects to incur and the need to generate sufficient cash flows to service and repay such debt.
• The possibility that the transaction may be more expensive to complete than anticipated.
• Diversion of management's attention from ongoing business operations and opportunities.
• Potential adverse reactions or changes to business or employee relationships resulting from the announcement or completion of the transaction.
• Risks relating to the potential dilutive effect of shares of BioCryst common stock to be issued in the merger.
• BioCryst's HAE portfolio and revenue growth expectations may not be achieved due to government actions, pricing decisions for navenibart, or regulatory agency decisions (e.g., FDA withholding or delaying approval, imposing restrictions, or clinical holds).
• Navenibart, if approved, may not achieve market acceptance.
• Sustainability of profitability and positive cash flow, and anticipated cash balance, may not meet management's expectations.
• Actual financial results may not be consistent with expectations, including revenue, operating expenses, and cash usage.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results, and early clinical trial outcomes may not be predictive of later trials.

Future Outlook

BioCryst anticipates continued profitability (non-GAAP) and positive cash flow following the transaction. The acquisition is expected to transform BioCryst's long-term revenue growth trajectory, extending double-digit revenue growth through the next decade, with the transaction being accretive to operating profit (non-GAAP) in the first full year of navenibart's anticipated launch. Topline data from navenibart's pivotal ALPHA-ORBIT trial is expected in early 2027. BioCryst projects a cash balance of over $1 billion by 2029, enabling optionality for other growth opportunities.

Management Comments

• Jon Stonehouse (CEO, BioCryst): "We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference."
• Jon Stonehouse (CEO, BioCryst): "Navenibart can emerge as the injectable of choice for patients seeking infrequent, pain-free dosing, strong attack control, and a mechanism of action they know and understand."
• Jon Stonehouse (CEO, BioCryst): "With our leading product, Orladeyo, and navenibarts potentially best-in-class profile, we will be well-positioned to drive sustainable growth and profitability while optimally serving the HAE patient community."
• Jill C. Milne (CEO, Astria Therapeutics): "We are thrilled to have navenibart become an integral part of BioCrysts HAE portfolio, advancing our shared mission of empowering patients to live beyond the limitations of their disease."
• Jill C. Milne (CEO, Astria Therapeutics): "We have great confidence in BioCrysts proven expertise and ability to successfully bring navenibart to patients who need better options for managing HAE and improving their quality of life."
• Jill C. Milne (CEO, Astria Therapeutics): "Importantly, this transaction represents a compelling outcome for Astria stockholders, providing cash for their shares at closing as well as continued ownership of BioCryst."
• Jill C. Milne (CEO, Astria Therapeutics): "I am incredibly proud of our talented Astria team, whose dedication and hard work have brought us to this important milestone."

Industry Context

The HAE market is experiencing innovation in prophylaxis, with a significant addressable market of over 5,000 patients in the US treated with injectable prophylaxis. BioCryst, already a player with its oral therapy ORLADEYO, is strategically expanding its offerings to include a potentially best-in-class injectable, navenibart. This move positions BioCryst to cater to a broader spectrum of patient preferences (oral vs. injectable) and address unmet needs in the injectable segment, particularly for longer-acting, pain-free options, thereby strengthening its market leadership in HAE.

Comparison to Industry Standards

• Navenibart's Phase 1b/2 data (ALPHA-STAR and ALPHA-SOLAR) demonstrated a mean attack rate reduction of 91-95% and 92% respectively, with 0% injection site pain and a highly differentiated dosing schedule of 2 or 4 doses per year (every 3 or 6 months).
• In comparison, lanadelumab (TAKHZYRO) showed an 87% attack rate reduction, but with 52% injection site pain and 26 doses per year (300 mg Q2W).
• Garadacimab achieved an 87% attack rate reduction with 12 doses per year (200 mg Q1M), but injection site pain data was not reported.
• Donidalorsen demonstrated an 81% attack rate reduction with 13 doses per year (80 mg Q4W), with injection site pain data not reported.
• Navenibart's profile, emphasizing infrequent, pain-free dosing and strong attack control, positions it as a potential best-in-class injectable prophylactic therapy, offering significant improvements over existing injectable options in terms of treatment burden and patient experience.

Management Changes

Corporate Governance

Legal Proceedings

• The filing acknowledges the possibility of legal proceedings being instituted against BioCryst or Astria related to the merger.
• The Company is obligated to promptly advise Parent of any 'Transaction Litigation' (actions related to the merger) and provide Parent with the opportunity to participate in its defense, prosecution, settlement, or compromise.

Related Party Transactions

• Certain stockholders of Astria, including each director and executive officer, and affiliates of Perceptive Advisors L.L.C. (Astria's largest stockholder as of October 13, 2025), entered into voting and support agreements with BioCryst.
• These agreements commit these stockholders to vote their shares of Astria Common Stock in favor of the merger and, with certain exceptions, not to transfer such shares prior to the earlier of the Effective Time or the termination of the Merger Agreement.
• Stockholders party to a Voting Agreement who also hold Series X Preferred Shares or Astria Common Warrants confirmed and consented to the treatment of these securities as set forth in the Merger Agreement and determined their Astria Common Warrants would be 'Elected Warrants'.

Stakeholder Impact

• **Shareholders (Astria)**: Will receive a significant premium for their shares, comprising both cash and BioCryst common stock, and will hold approximately 15% of the combined company, offering continued participation in future growth.
• **Shareholders (BioCryst)**: Face potential dilution from the issuance of new shares and increased debt, but stand to benefit from an expanded, diversified HAE portfolio, projected double-digit revenue growth, and enhanced long-term profitability.
• **Patients (HAE)**: Will gain access to a broader range of HAE prophylaxis options, including a potentially best-in-class injectable (navenibart) with a highly convenient dosing schedule and pain-free administration, addressing significant unmet needs.
• **Employees (Astria)**: The merger agreement includes provisions for 'Continuing Employees' ensuring comparable base salary, annual target bonus opportunities, and severance benefits for one year post-merger, and recognition of prior service for vesting and eligibility in Parent Benefit Plans. Jill C. Milne, Astria's CEO, will join BioCryst's board.
• **Creditors**: BioCryst has paid off its previous loan agreement and secured a new $550 million debt facility from Blackstone, altering its debt profile and potentially increasing its leverage.

Next Steps

• Astria stockholders must vote to adopt the Merger Agreement.
• The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act must expire or be terminated early.
• BioCryst's registration statement on Form S-4 must become effective with the SEC.
• The shares of BioCryst common stock to be issued in the merger must be approved for listing on Nasdaq.
• The merger is expected to close in the first quarter of 2026.
• Jill C. Milne, Ph.D. will join the BioCryst board of directors upon the closing of the merger.
• Topline data from navenibart's pivotal ALPHA-ORBIT trial is expected in early 2027.
• BioCryst plans to seek strategic alternatives for Astria's early-stage program for atopic dermatitis, STAR-0310.
• Astria Common Stock will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934 upon consummation of the merger.

Key Dates

Recommendation

The acquisition of Astria Therapeutics by BioCryst Pharmaceuticals is a highly strategic move that significantly enhances BioCryst's position in the Hereditary Angioedema (HAE) market. Navenibart, the lead asset from Astria, is a late-stage, potentially best-in-class injectable HAE prophylactic with a highly differentiated dosing schedule (every 3 or 6 months) and a pain-free administration profile, addressing a clear unmet need. This complements BioCryst's existing oral HAE therapy, ORLADEYO, creating a comprehensive portfolio that caters to diverse patient preferences. The financial terms, while involving new debt, are structured to maintain BioCryst's profitability and positive cash flow, with the transaction expected to be accretive to operating profit in the first full year post-launch. The projected double-digit revenue growth for the HAE portfolio into the next decade and a cash balance exceeding $1 billion by 2029 indicate strong long-term financial prospects. The premium paid for Astria shares reflects the strategic value of navenibart. This acquisition positions BioCryst for sustainable growth and market leadership in HAE, making it a compelling investment opportunity.

Keywords

BioCryst Pharmaceuticals, Astria Therapeutics, Merger, Acquisition, HAE, Hereditary Angioedema, Navenibart, ORLADEYO, Plasma Kallikrein Inhibitor, Rare Disease, Biotechnology, Pharmaceutical, Clinical Development, Phase 3, Debt Financing, Blackstone, Nasdaq, SEC Filing, Corporate Governance, Stockholder Approval